NZ535314A - Combination treatments for chemokine-mediated diseases - Google Patents

Info

Publication number

NZ535314A

NZ535314A NZ535314A NZ53531403A NZ535314A NZ 535314 A NZ535314 A NZ 535314A NZ 535314 A NZ535314 A NZ 535314A NZ 53531403 A NZ53531403 A NZ 53531403A NZ 535314 A NZ535314 A NZ 535314A

Authority

NZ

New Zealand

Prior art keywords

group

substituted

unsubstituted

compound

disease

Prior art date

2002-03-18

Links

• Espacenet
• Global Dossier
• Discuss

• 201000010099 disease Diseases 0.000 title claims abstract description 63
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 63
• 230000001404 mediated effect Effects 0.000 title claims abstract description 53
• 102000019034 Chemokines Human genes 0.000 title claims abstract description 39
• 108010012236 Chemokines Proteins 0.000 title claims abstract description 39
• 238000011284 combination treatment Methods 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims abstract description 281
• 150000003839 salts Chemical class 0.000 claims abstract description 63
• 239000003814 drug Substances 0.000 claims abstract description 54
• 239000012453 solvate Substances 0.000 claims abstract description 43
• 108050006947 CXC Chemokine Proteins 0.000 claims abstract description 30
• 102000019388 CXC chemokine Human genes 0.000 claims abstract description 30
• 238000004519 manufacturing process Methods 0.000 claims abstract description 13
• 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 12
• 208000006673 asthma Diseases 0.000 claims abstract description 12
• 201000004681 Psoriasis Diseases 0.000 claims abstract description 11
• 125000001424 substituent group Chemical group 0.000 claims description 203
• 125000000217 alkyl group Chemical group 0.000 claims description 159
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 84
• 125000001072 heteroaryl group Chemical group 0.000 claims description 70
• 239000000203 mixture Substances 0.000 claims description 66
• -1 -OH Chemical group 0.000 claims description 63
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
• 229910052736 halogen Inorganic materials 0.000 claims description 54
• 150000002367 halogens Chemical class 0.000 claims description 53
• 238000011282 treatment Methods 0.000 claims description 50
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 45
• 125000003118 aryl group Chemical group 0.000 claims description 37
• 238000006243 chemical reaction Methods 0.000 claims description 35
• 229910052739 hydrogen Inorganic materials 0.000 claims description 34
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 32
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
• 125000000623 heterocyclic group Chemical group 0.000 claims description 30
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 30
• 206010040070 Septic Shock Diseases 0.000 claims description 27
• 241000700605 Viruses Species 0.000 claims description 27
• 229910052757 nitrogen Inorganic materials 0.000 claims description 27
• 125000003107 substituted aryl group Chemical group 0.000 claims description 26
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
• 239000001257 hydrogen Substances 0.000 claims description 21
• 206010061218 Inflammation Diseases 0.000 claims description 20
• 125000003545 alkoxy group Chemical group 0.000 claims description 20
• 206010003246 arthritis Diseases 0.000 claims description 20
• 230000004054 inflammatory process Effects 0.000 claims description 20
• 239000005557 antagonist Substances 0.000 claims description 19
• 239000003795 chemical substances by application Substances 0.000 claims description 19
• 206010011224 Cough Diseases 0.000 claims description 18
• 206010021143 Hypoxia Diseases 0.000 claims description 18
• 229940079593 drug Drugs 0.000 claims description 18
• 208000014674 injury Diseases 0.000 claims description 18
• 229910052760 oxygen Inorganic materials 0.000 claims description 18
• 208000023504 respiratory system disease Diseases 0.000 claims description 18
• 230000008733 trauma Effects 0.000 claims description 18
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
• 239000003112 inhibitor Substances 0.000 claims description 16
• 206010063837 Reperfusion injury Diseases 0.000 claims description 15
• 229960000905 indomethacin Drugs 0.000 claims description 15
• 208000006011 Stroke Diseases 0.000 claims description 14
• 230000000747 cardiac effect Effects 0.000 claims description 14
• 150000002431 hydrogen Chemical class 0.000 claims description 14
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
• 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 14
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
• 229910052717 sulfur Inorganic materials 0.000 claims description 13
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 11
• 208000019693 Lung disease Diseases 0.000 claims description 11
• 230000002378 acidificating effect Effects 0.000 claims description 11
• 201000006417 multiple sclerosis Diseases 0.000 claims description 11
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 11
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 10
• 125000000524 functional group Chemical group 0.000 claims description 10
• 229960000485 methotrexate Drugs 0.000 claims description 10
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 9
• 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims description 9
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 9
• 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 9
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 201000001320 Atherosclerosis Diseases 0.000 claims description 9
• 201000006474 Brain Ischemia Diseases 0.000 claims description 9
• 206010006448 Bronchiolitis Diseases 0.000 claims description 9
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 9
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 9
• 206010009137 Chronic sinusitis Diseases 0.000 claims description 9
• 208000015943 Coeliac disease Diseases 0.000 claims description 9
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 9
• 208000034656 Contusions Diseases 0.000 claims description 9
• 206010055665 Corneal neovascularisation Diseases 0.000 claims description 9
• 208000011231 Crohn disease Diseases 0.000 claims description 9
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
• 208000000059 Dyspnea Diseases 0.000 claims description 9
• 206010013975 Dyspnoeas Diseases 0.000 claims description 9
• 206010014561 Emphysema Diseases 0.000 claims description 9
• 206010014824 Endotoxic shock Diseases 0.000 claims description 9
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 9
• 208000005232 Glossitis Diseases 0.000 claims description 9
• 201000005569 Gout Diseases 0.000 claims description 9
• 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 9
• 206010058490 Hyperoxia Diseases 0.000 claims description 9
• 206010020751 Hypersensitivity Diseases 0.000 claims description 9
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 9
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 9
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 9
• 201000009906 Meningitis Diseases 0.000 claims description 9
• 206010051606 Necrotising colitis Diseases 0.000 claims description 9
• 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 9
• 206010061876 Obstruction Diseases 0.000 claims description 9
• 208000022873 Ocular disease Diseases 0.000 claims description 9
• 206010030216 Oesophagitis Diseases 0.000 claims description 9
• 208000001132 Osteoporosis Diseases 0.000 claims description 9
• 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 9
• 208000003251 Pruritus Diseases 0.000 claims description 9
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 9
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 9
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 9
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 9
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 9
• 208000000924 Right ventricular hypertrophy Diseases 0.000 claims description 9
• 206010040047 Sepsis Diseases 0.000 claims description 9
• 208000010040 Sprains and Strains Diseases 0.000 claims description 9
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 9
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 9
• 208000007536 Thrombosis Diseases 0.000 claims description 9
• 206010044248 Toxic shock syndrome Diseases 0.000 claims description 9
• 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 9
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 9
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 9
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 9
• 206010047115 Vasculitis Diseases 0.000 claims description 9
• 206010047924 Wheezing Diseases 0.000 claims description 9
• 206010000496 acne Diseases 0.000 claims description 9
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 9
• 230000010085 airway hyperresponsiveness Effects 0.000 claims description 9
• 208000002353 alcoholic hepatitis Diseases 0.000 claims description 9
• 125000003342 alkenyl group Chemical group 0.000 claims description 9
• 125000000304 alkynyl group Chemical group 0.000 claims description 9
• 208000026935 allergic disease Diseases 0.000 claims description 9
• 230000002491 angiogenic effect Effects 0.000 claims description 9
• 201000008937 atopic dermatitis Diseases 0.000 claims description 9
• 201000009267 bronchiectasis Diseases 0.000 claims description 9
• 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 9
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 9
• 206010006451 bronchitis Diseases 0.000 claims description 9
• 208000025997 central nervous system neoplasm Diseases 0.000 claims description 9
• 208000010353 central nervous system vasculitis Diseases 0.000 claims description 9
• 230000002490 cerebral effect Effects 0.000 claims description 9
• 206010008118 cerebral infarction Diseases 0.000 claims description 9
• 208000007451 chronic bronchitis Diseases 0.000 claims description 9
• 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 9
• 230000009519 contusion Effects 0.000 claims description 9
• 201000000159 corneal neovascularization Diseases 0.000 claims description 9
• 239000013078 crystal Substances 0.000 claims description 9
• 238000000502 dialysis Methods 0.000 claims description 9
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 9
• 208000000718 duodenal ulcer Diseases 0.000 claims description 9
• 230000004064 dysfunction Effects 0.000 claims description 9
• 208000000292 ehrlichiosis Diseases 0.000 claims description 9
• 206010014599 encephalitis Diseases 0.000 claims description 9
• 208000006881 esophagitis Diseases 0.000 claims description 9
• 230000002496 gastric effect Effects 0.000 claims description 9
• 208000007565 gingivitis Diseases 0.000 claims description 9
• 208000006454 hepatitis Diseases 0.000 claims description 9
• 231100000283 hepatitis Toxicity 0.000 claims description 9
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
• 230000000222 hyperoxic effect Effects 0.000 claims description 9
• 230000009610 hypersensitivity Effects 0.000 claims description 9
• 208000018875 hypoxemia Diseases 0.000 claims description 9
• 230000007954 hypoxia Effects 0.000 claims description 9
• 210000004072 lung Anatomy 0.000 claims description 9
• 206010025135 lupus erythematosus Diseases 0.000 claims description 9
• 208000002780 macular degeneration Diseases 0.000 claims description 9
• 201000004792 malaria Diseases 0.000 claims description 9
• 208000031225 myocardial ischemia Diseases 0.000 claims description 9
• 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 9
• 201000008482 osteoarthritis Diseases 0.000 claims description 9
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 9
• 201000001245 periodontitis Diseases 0.000 claims description 9
• 206010034674 peritonitis Diseases 0.000 claims description 9
• 208000005987 polymyositis Diseases 0.000 claims description 9
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 9
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 9
• 230000000241 respiratory effect Effects 0.000 claims description 9
• 201000000306 sarcoidosis Diseases 0.000 claims description 9
• 230000036303 septic shock Effects 0.000 claims description 9
• 238000002560 therapeutic procedure Methods 0.000 claims description 9
• 238000002054 transplantation Methods 0.000 claims description 9
• 230000009529 traumatic brain injury Effects 0.000 claims description 9
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
• 230000005951 type IV hypersensitivity Effects 0.000 claims description 9
• 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 9
• 241001529453 unidentified herpesvirus Species 0.000 claims description 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
• 125000005842 heteroatom Chemical group 0.000 claims description 8
• 150000003431 steroids Chemical class 0.000 claims description 8
• 108090000174 Interleukin-10 Proteins 0.000 claims description 7
• 102000003814 Interleukin-10 Human genes 0.000 claims description 7
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
• 229940111134 coxibs Drugs 0.000 claims description 7
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 238000009472 formulation Methods 0.000 claims description 7
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 7
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 7
• 229960002702 piroxicam Drugs 0.000 claims description 7
• 239000000556 agonist Substances 0.000 claims description 6
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
• 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 159000000000 sodium salts Chemical class 0.000 claims description 6
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
• 229930105110 Cyclosporin A Natural products 0.000 claims description 5
• 108010036949 Cyclosporine Proteins 0.000 claims description 5
• 108010002352 Interleukin-1 Proteins 0.000 claims description 5
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 5
• 229940124761 MMP inhibitor Drugs 0.000 claims description 5
• 239000002559 chemokine receptor antagonist Substances 0.000 claims description 5
• 229960001265 ciclosporin Drugs 0.000 claims description 5
• 229930182912 cyclosporin Natural products 0.000 claims description 5
• 239000003862 glucocorticoid Substances 0.000 claims description 5
• 230000001506 immunosuppresive effect Effects 0.000 claims description 5
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 5
• 230000003551 muscarinic effect Effects 0.000 claims description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
• 229960004618 prednisone Drugs 0.000 claims description 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
• 229960001940 sulfasalazine Drugs 0.000 claims description 5
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 5
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 4
• WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
• 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 4
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 4
• 159000000007 calcium salts Chemical class 0.000 claims description 4
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 4
• 229960004397 cyclophosphamide Drugs 0.000 claims description 4
• 239000003172 expectorant agent Substances 0.000 claims description 4
• 150000002343 gold Chemical class 0.000 claims description 4
• 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 4
• 229960001680 ibuprofen Drugs 0.000 claims description 4
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 4
• 229960000991 ketoprofen Drugs 0.000 claims description 4
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 4
• 229950007856 mofetil Drugs 0.000 claims description 4
• 229940014456 mycophenolate Drugs 0.000 claims description 4
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 4
• 229960002009 naproxen Drugs 0.000 claims description 4
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
• 229960001639 penicillamine Drugs 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
• 229940124639 Selective inhibitor Drugs 0.000 claims description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
• 239000003146 anticoagulant agent Substances 0.000 claims description 3
• 229940127219 anticoagulant drug Drugs 0.000 claims description 3
• 229940127218 antiplatelet drug Drugs 0.000 claims description 3
• 230000008512 biological response Effects 0.000 claims description 3
• 239000011575 calcium Substances 0.000 claims description 3
• 229910052791 calcium Inorganic materials 0.000 claims description 3
• 229960000590 celecoxib Drugs 0.000 claims description 3
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
• 229960004544 cortisone Drugs 0.000 claims description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
• 230000016396 cytokine production Effects 0.000 claims description 3
• 229960003957 dexamethasone Drugs 0.000 claims description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
• 238000012986 modification Methods 0.000 claims description 3
• 230000004048 modification Effects 0.000 claims description 3
• 239000003607 modifier Substances 0.000 claims description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 3
• 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 3
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
• 229960000371 rofecoxib Drugs 0.000 claims description 3
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
• 229960002930 sirolimus Drugs 0.000 claims description 3
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
• 150000003384 small molecules Chemical class 0.000 claims description 3
• 229960001967 tacrolimus Drugs 0.000 claims description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
• 229960003433 thalidomide Drugs 0.000 claims description 3
• GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 claims description 2
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 claims description 2
• 102000017910 Adrenergic receptor Human genes 0.000 claims description 2
• 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 2
• 108010056764 Eptifibatide Proteins 0.000 claims description 2
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
• 108090000622 Nociceptin Proteins 0.000 claims description 2
• 108090000553 Phospholipase D Proteins 0.000 claims description 2
• 102000011420 Phospholipase D Human genes 0.000 claims description 2
• 108010039185 Tenecteplase Proteins 0.000 claims description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
• 229960000446 abciximab Drugs 0.000 claims description 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
• 239000002597 adenosine A2 receptor agonist Substances 0.000 claims description 2
• 229960003318 alteplase Drugs 0.000 claims description 2
• 239000003963 antioxidant agent Substances 0.000 claims description 2
• 229940124630 bronchodilator Drugs 0.000 claims description 2
• 239000000168 bronchodilator agent Substances 0.000 claims description 2
• 239000000850 decongestant Substances 0.000 claims description 2
• 229940124581 decongestants Drugs 0.000 claims description 2
• 229940052760 dopamine agonists Drugs 0.000 claims description 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
• 239000003602 elastase inhibitor Substances 0.000 claims description 2
• GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 claims description 2
• 229960004468 eptifibatide Drugs 0.000 claims description 2
• 230000003419 expectorant effect Effects 0.000 claims description 2
• 229940066493 expectorants Drugs 0.000 claims description 2
• 229960003776 glatiramer acetate Drugs 0.000 claims description 2
• 239000000122 growth hormone Substances 0.000 claims description 2
• 229960002897 heparin Drugs 0.000 claims description 2
• 229920000669 heparin Polymers 0.000 claims description 2
• 239000000938 histamine H1 antagonist Substances 0.000 claims description 2
• 239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 2
• 229960000598 infliximab Drugs 0.000 claims description 2
• 229940079322 interferon Drugs 0.000 claims description 2
• 229940043355 kinase inhibitor Drugs 0.000 claims description 2
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims description 2
• 229940066491 mucolytics Drugs 0.000 claims description 2
• PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims description 2
• 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
• 230000000770 proinflammatory effect Effects 0.000 claims description 2
• 229960000216 tenecteplase Drugs 0.000 claims description 2
• 230000001225 therapeutic effect Effects 0.000 claims description 2
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
• 102000048266 Nociceptin Human genes 0.000 claims 1
• 229960005205 prednisolone Drugs 0.000 claims 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
• 230000001154 acute effect Effects 0.000 abstract description 2
• 208000037976 chronic inflammation Diseases 0.000 abstract description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 abstract description 2
• 206010028980 Neoplasm Diseases 0.000 abstract 1
• 201000011510 cancer Diseases 0.000 abstract 1
• 238000000034 method Methods 0.000 description 183
• 239000000047 product Substances 0.000 description 80
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
• 239000000243 solution Substances 0.000 description 44
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 35
• 239000012267 brine Substances 0.000 description 33
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 33
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
• 229910001868 water Inorganic materials 0.000 description 33
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
• 150000001412 amines Chemical class 0.000 description 28
• 239000010410 layer Substances 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• 230000005764 inhibitory process Effects 0.000 description 24
• 238000003556 assay Methods 0.000 description 22
• 239000012131 assay buffer Substances 0.000 description 22
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 19
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 19
• 239000011541 reaction mixture Substances 0.000 description 19
• 229940126062 Compound A Drugs 0.000 description 18
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 18
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 17
• 239000012528 membrane Substances 0.000 description 17
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 16
• 125000004432 carbon atom Chemical group C* 0.000 description 16
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 16
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
• 239000007864 aqueous solution Substances 0.000 description 15
• 239000011324 bead Substances 0.000 description 15
• 239000000543 intermediate Substances 0.000 description 15
• RGBVWCQARBEPPW-UHFFFAOYSA-N cyclobut-3-ene-1,2-dione Chemical compound O=C1C=CC1=O RGBVWCQARBEPPW-UHFFFAOYSA-N 0.000 description 14
• 239000000284 extract Substances 0.000 description 14
• 239000003446 ligand Substances 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
• 239000007787 solid Substances 0.000 description 13
• 239000002904 solvent Substances 0.000 description 13
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 239000002253 acid Substances 0.000 description 11
• 239000012044 organic layer Substances 0.000 description 11
• 125000006413 ring segment Chemical group 0.000 description 11
• 150000001299 aldehydes Chemical class 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 150000002466 imines Chemical class 0.000 description 10
• 150000002576 ketones Chemical class 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• 102100026236 Interleukin-8 Human genes 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 239000000706 filtrate Substances 0.000 description 9
• 229910052731 fluorine Inorganic materials 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 8
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
• ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
• 108090001007 Interleukin-8 Proteins 0.000 description 7
• 238000009833 condensation Methods 0.000 description 7
• 230000005494 condensation Effects 0.000 description 7
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 7
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
• 229940096397 interleukin-8 Drugs 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• 239000007995 HEPES buffer Substances 0.000 description 6
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• 125000004122 cyclic group Chemical group 0.000 description 6
• 210000002683 foot Anatomy 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 229910000027 potassium carbonate Inorganic materials 0.000 description 6
• 238000010898 silica gel chromatography Methods 0.000 description 6
• 229910052938 sodium sulfate Inorganic materials 0.000 description 6
• 235000011152 sodium sulphate Nutrition 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
• 229960002537 betamethasone Drugs 0.000 description 5
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 5
• 238000001816 cooling Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• QBZXOWQOWPHHRA-UHFFFAOYSA-N lithium;ethane Chemical compound [Li+].[CH2-]C QBZXOWQOWPHHRA-UHFFFAOYSA-N 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 239000000741 silica gel Substances 0.000 description 5
• 229910002027 silica gel Inorganic materials 0.000 description 5
• 239000011550 stock solution Substances 0.000 description 5
• 230000008961 swelling Effects 0.000 description 5
• RPCHNECSJGMRGP-UHFFFAOYSA-N 3-Ethylfuran Chemical compound CCC=1C=COC=1 RPCHNECSJGMRGP-UHFFFAOYSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 150000001414 amino alcohols Chemical class 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 239000012458 free base Substances 0.000 description 4
• 210000000548 hind-foot Anatomy 0.000 description 4
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
• HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 4
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 4
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
• 235000019341 magnesium sulphate Nutrition 0.000 description 4
• 125000001979 organolithium group Chemical group 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000000611 regression analysis Methods 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 125000004434 sulfur atom Chemical group 0.000 description 4
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
• 102000003896 Myeloperoxidases Human genes 0.000 description 3
• 108090000235 Myeloperoxidases Proteins 0.000 description 3
• 150000001204 N-oxides Chemical class 0.000 description 3
• 229910006074 SO2NH2 Inorganic materials 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 150000008064 anhydrides Chemical class 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 125000001246 bromo group Chemical group Br* 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 239000000679 carrageenan Substances 0.000 description 3
• 235000010418 carrageenan Nutrition 0.000 description 3
• 229940113118 carrageenan Drugs 0.000 description 3
• 229920001525 carrageenan Polymers 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 125000001309 chloro group Chemical group Cl* 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
• 229960002986 dinoprostone Drugs 0.000 description 3
• 239000012039 electrophile Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• 210000003127 knee Anatomy 0.000 description 3
• 210000000629 knee joint Anatomy 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 239000001632 sodium acetate Substances 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
• KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
• PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
• DFSFLZCLKYZYRD-UHFFFAOYSA-N 3,4-diethoxycyclobut-3-ene-1,2-dione Chemical compound CCOC1=C(OCC)C(=O)C1=O DFSFLZCLKYZYRD-UHFFFAOYSA-N 0.000 description 2
• GDDNTTHUKVNJRA-UHFFFAOYSA-N 3-bromo-3,3-difluoroprop-1-ene Chemical compound FC(F)(Br)C=C GDDNTTHUKVNJRA-UHFFFAOYSA-N 0.000 description 2
• SBTKGYVVXLMMQE-UHFFFAOYSA-N 3-butylfuran Chemical compound CCCCC=1C=COC=1 SBTKGYVVXLMMQE-UHFFFAOYSA-N 0.000 description 2
• RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 2
• HLKHDXRCRNEXSF-UHFFFAOYSA-N 3-methoxythiophene-2-sulfonyl chloride Chemical compound COC=1C=CSC=1S(Cl)(=O)=O HLKHDXRCRNEXSF-UHFFFAOYSA-N 0.000 description 2
• OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 102000001902 CC Chemokines Human genes 0.000 description 2
• 108010040471 CC Chemokines Proteins 0.000 description 2
• 229940124638 COX inhibitor Drugs 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• 241000534944 Thia Species 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 239000003435 antirheumatic agent Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229910000085 borane Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 2
• SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical class ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 150000002440 hydroxy compounds Chemical class 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229960005127 montelukast Drugs 0.000 description 2
• FYTRVVJHEWUARG-UHFFFAOYSA-N n-(2-aminophenyl)nitramide Chemical class NC1=CC=CC=C1N[N+]([O-])=O FYTRVVJHEWUARG-UHFFFAOYSA-N 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• FLBKPDIBGNWXMT-NIQZGXKPSA-N (2r,3r,4s,5r)-2-[6-amino-2-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(2-ethyltetrazol-5-yl)oxolane-3,4-diol Chemical compound CCN1N=NC([C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC(N[C@H](CO)CC=4C=CC=CC=4)=NC(N)=C3N=C2)O)=N1 FLBKPDIBGNWXMT-NIQZGXKPSA-N 0.000 description 1
• BUMMZWFWCNQFPS-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-n,n-di(propan-2-yl)benzamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 BUMMZWFWCNQFPS-BTJKTKAUSA-N 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• RHXUHAVACBNNSU-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-1-(3,4,5-trimethoxyphenyl)urea Chemical compound COC1=CC(N(CCN(C)C)C(N)=O)=CC(OC)=C1OC RHXUHAVACBNNSU-UHFFFAOYSA-N 0.000 description 1
• YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
• VGZREXZCXACRQU-UHFFFAOYSA-N 2-aminothiophen-3-ol Chemical compound NC=1SC=CC=1O VGZREXZCXACRQU-UHFFFAOYSA-N 0.000 description 1
• RFPCDZUEOAPQTC-UHFFFAOYSA-N 2-benzylsulfonyl-3-ethylthiophene Chemical compound C1=CSC(S(=O)(=O)CC=2C=CC=CC=2)=C1CC RFPCDZUEOAPQTC-UHFFFAOYSA-N 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 1
• KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
• GZJIQNJINXQYTG-UHFFFAOYSA-N 2-nitrooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O[N+]([O-])=O GZJIQNJINXQYTG-UHFFFAOYSA-N 0.000 description 1
• FIDWUJWRKJJJLL-UHFFFAOYSA-N 3-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]-n-[2-[2-(4-methylphenyl)ethoxy]ethyl]propane-1-sulfonamide Chemical compound C1=CC(C)=CC=C1CCOCCNS(=O)(=O)CCCNCCC1=CC=C(O)C2=C1SC(=O)N2 FIDWUJWRKJJJLL-UHFFFAOYSA-N 0.000 description 1
• PIBPHOFXQUUPTM-UHFFFAOYSA-N 3-bromo-2-methoxybenzoic acid Chemical compound COC1=C(Br)C=CC=C1C(O)=O PIBPHOFXQUUPTM-UHFFFAOYSA-N 0.000 description 1
• DXAQRDRNGATBSU-UHFFFAOYSA-N 3-butylfuran-2-carbaldehyde Chemical compound CCCCC=1C=COC=1C=O DXAQRDRNGATBSU-UHFFFAOYSA-N 0.000 description 1
• AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
• BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
• OWIRCRREDNEXTA-UHFFFAOYSA-N 3-nitro-1h-indazole Chemical compound C1=CC=C2C([N+](=O)[O-])=NNC2=C1 OWIRCRREDNEXTA-UHFFFAOYSA-N 0.000 description 1
• CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 1
• KYOQLZOZPDVYCB-UHFFFAOYSA-N 4-ethylfuran-2-carbaldehyde Chemical compound CCC1=COC(C=O)=C1 KYOQLZOZPDVYCB-UHFFFAOYSA-N 0.000 description 1
• UTMDJGPRCLQPBT-UHFFFAOYSA-N 4-nitro-1h-1,2,3-benzotriazole Chemical compound [O-][N+](=O)C1=CC=CC2=NNN=C12 UTMDJGPRCLQPBT-UHFFFAOYSA-N 0.000 description 1
• MQLADKMVHOOVET-HXPMCKFVSA-N 5-[4-[(2s,4r)-4-hydroxy-2-methyloxan-4-yl]thiophen-2-yl]sulfanyl-1-methyl-3h-indol-2-one Chemical compound C1CO[C@@H](C)C[C@@]1(O)C1=CSC(SC=2C=C3CC(=O)N(C)C3=CC=2)=C1 MQLADKMVHOOVET-HXPMCKFVSA-N 0.000 description 1
• VXPXTXPNYIZMLU-UHFFFAOYSA-N 5-bromo-4-tert-butyl-2-ethyl-3H-furan-2-carboxylic acid Chemical compound CCC1(C(O)=O)CC(C(C)(C)C)=C(Br)O1 VXPXTXPNYIZMLU-UHFFFAOYSA-N 0.000 description 1
• YVTQHZDUDUCGRD-UHFFFAOYSA-N 5-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)O1 YVTQHZDUDUCGRD-UHFFFAOYSA-N 0.000 description 1
• FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 241000349731 Afzelia bipindensis Species 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
• 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
• 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
• 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
• 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
• 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
• 108010084313 CD58 Antigens Proteins 0.000 description 1
• 229940123441 CXC chemokine receptor antagonist Drugs 0.000 description 1
• 108091008928 CXC chemokine receptors Proteins 0.000 description 1
• 102000054900 CXCR Receptors Human genes 0.000 description 1
• LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
• 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
• 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 101710139422 Eotaxin Proteins 0.000 description 1
• 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
• 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102100022339 Integrin alpha-L Human genes 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• 102400001111 Nociceptin Human genes 0.000 description 1
• 102100030304 Platelet factor 4 Human genes 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• 229910008433 SnCU Inorganic materials 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• VGXACJMXDYPFDB-SXMMONRFSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (2s)-2-(hydroxymethyl)-4-[(r)-methylsulfinyl]-2-phenylbutanoate Chemical compound C1([C@@](CO)(C(=O)O[C@@H]2C3CCN(CC3)C2)CC[S@](=O)C)=CC=CC=C1 VGXACJMXDYPFDB-SXMMONRFSA-N 0.000 description 1
• YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 229960002459 alefacept Drugs 0.000 description 1
• 125000004946 alkenylalkyl group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000005038 alkynylalkyl group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229940092705 beclomethasone Drugs 0.000 description 1
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical class C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 229960003728 ciclesonide Drugs 0.000 description 1
• 229950001653 cilomilast Drugs 0.000 description 1
• 238000007398 colorimetric assay Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 229960001271 desloratadine Drugs 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000002497 edematous effect Effects 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 229960002848 formoterol Drugs 0.000 description 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• STJIISDMSMJQQK-UHFFFAOYSA-N furan-3-ylmethanol Chemical compound OCC=1C=COC=1 STJIISDMSMJQQK-UHFFFAOYSA-N 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000005337 ground glass Substances 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
• CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000005945 imidazopyridyl group Chemical group 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 229960004078 indacaterol Drugs 0.000 description 1
• QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229940076144 interleukin-10 Drugs 0.000 description 1
• 230000021995 interleukin-8 production Effects 0.000 description 1
• 102000010681 interleukin-8 receptors Human genes 0.000 description 1
• 108010038415 interleukin-8 receptors Proteins 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229960001361 ipratropium bromide Drugs 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960001664 mometasone Drugs 0.000 description 1
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• DDMWNBLSVDHIFH-UHFFFAOYSA-N n'-hydroxythiophene-2-sulfonohydrazide Chemical compound ONNS(=O)(=O)C1=CC=CS1 DDMWNBLSVDHIFH-UHFFFAOYSA-N 0.000 description 1
• JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
• BHCJHYIMNHXLOM-WVDRJWPYSA-N n-[(e,2r)-1-(3,4-dichlorophenyl)-5-oxo-5-[[(3r)-2-oxoazepan-3-yl]amino]pent-3-en-2-yl]-n-methyl-3,5-bis(trifluoromethyl)benzamide Chemical compound C([C@@H](N(C)C(=O)C=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)\C=C\C(=O)N[C@H]1C(NCCCC1)=O)C1=CC=C(Cl)C(Cl)=C1 BHCJHYIMNHXLOM-WVDRJWPYSA-N 0.000 description 1
• HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 description 1
• 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000006606 n-butoxy group Chemical group 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 125000004971 nitroalkyl group Chemical group 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 239000003605 opacifier Substances 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229950010090 pumafentrine Drugs 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 229950000915 revatropate Drugs 0.000 description 1
• MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
• 229960002586 roflumilast Drugs 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 229960004017 salmeterol Drugs 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 150000003378 silver Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229950011332 talnetant Drugs 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229960000257 tiotropium bromide Drugs 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 125000005023 xylyl group Chemical group 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1